Screener / SEC EDGAR /CIK 0002019410 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Caris Life Sciences, Inc. CAI

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. 10-K, Item 1

Employees
1,846
Headquarters
Irving, TX
Next results
around Jan 11, 2027
Compare with peers Embed

CAI among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 97.0%, above 96% of 154 peers (their median 10.4%) REVENUE GROWTH 97.0% · above 96% Operating margin: 13.4%, above 63% of 138 peers (their median 9.8%) OPERATING MARGIN 13.4% · above 63% Net margin: 9.2%, above 57% of 153 peers (their median 6.7%) NET MARGIN 9.2% · above 57% FCF margin: 2.8%, above 26% of 144 peers (their median 10.1%) FCF MARGIN 2.8% · above 26%
CAI Peer median Below the median

What changed

Nothing new in the latest 10-K.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

9 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 9 checks found nothing to note

  • Receivables +27.1% ($88.2M to $112.1M) vs revenue +97.0% ($412.3M to $812.0M), -69.9 pts apart
  • Cash from operations $83.2M vs net income −$68.1M (FY ending Dec 31, 2025)
  • Auditor names not available for both 10-Ks; no 8-K item 4.01
6 more checks with nothing to note
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

No new paragraphs in Risk Factors

No new paragraphs in Risk Factors, or fewer than two 10-Ks to compare.

Financial performance

Last 3 fiscal years · 10-K XBRL

All years
MetricFY2023FY2024FY2025
Revenue$306.1M$412.3M$812.0M
Net income−$341.4M−$281.9M−$68.1M
Operating cash flow−$276.1M−$245.2M$83.2M
Free cash flow−$298.4M−$253.6M$66.9M

Revenue, FY2023 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$812.0M ▲ 97.0% in FY2025

FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

Caris Life Sciences, Inc., Irving, TX · from the 10-K filed Mar 3, 2026

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.

Headquarters
Irving, TX
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 4, 2026
Incorporated in
TX

Employees, at the top of the page: "As of December 31, 2025, we had 1,846 employees" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CAI/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.